Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 9/20 | 0.44 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.44 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | DUT | P33316 | 3/20 | 0.37 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.36 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25233938 | 1.00 | SLC28A1 (0.48) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL11872658 | 0.88 | SLC28A1 (0.38) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4264643 | 0.82 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4268211 | 0.82 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4268214 | 0.82 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL11896632 | 0.82 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4271593 | 0.82 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4261094 | 0.82 | SLC28A1 (0.46) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL19185143 | 0.81 | SLC28A1 (0.44) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL17372031 | 0.81 | SLC28A1 (0.49) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4914195-A | Process for preparing N-acetylneuraminic acid derivatives | MECT CORPORATION (JP) | 1990-04-03 | — | — | US | claimed |
| US-4691012-A | INHIBITOR OF METASTASIS OF CANCER CELLS | MECT CORPORATION (JP) | 1987-09-01 | — | — | US | claimed |
| US-4447600-A | IMMUNOSUPPRESSIVE AGENTS | KANTO ISHI PHARMACEUTICAL CO., LTD. (JP) | 1984-05-08 | — | — | US | claimed |
| US-20260055125-A1 | LIGAND-ASSISTED DEOXYGENATION OF PHOSPHATES TO FORM NITROGEN-CONTAINING PHOSPHORUS(V) PRECURSORS AND THEIR SUBSEQUENT CONVERSION TO VARIOUS OXYPHOSPHORUS COMPOUNDS | UNIV DRESDEN TECH (DE) | 2026-02-26 | — | — | US | disclosed |
| US-12551497-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4433419-A1 | LIGAND-ASSISTED DEOXYGENATION OF PHOSPHATES TO FORM NITROGEN-CONTAINING PHOSPHORUS(V) PRECURSORS AND THEIR SUBSEQUENT CONVERSION TO VARIOUS OXYPHOSPHORUS COMPOUNDS | Technische Universität Dresden (DE) | 2024-09-25 | — | — | EP | disclosed |
| CN-118286245-A | N4-hydroxycytidine and derivatives and antiviral uses related thereto | 埃莫里大学 | 2024-07-05 | — | — | CN | disclosed |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | EMORY UNIVERSITY | 2023-09-21 | — | — | US | disclosed |
| WO-2023089031-A1 | LIGAND-ASSISTED DEOXYGENATION OF PHOSPHATES TO FORM NITROGEN-CONTAINING PHOSPHORUS(V) PRECURSORS AND THEIR SUBSEQUENT CONVERSION TO VARIOUS OXYPHOSPHORUS COMPOUNDS | Technische Universität Dresden (DE) | 2023-05-25 | — | — | WO | disclosed |
| US-11628181-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | EMORY UNIVERSITY (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3939985-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING N4-HYDROXYCYTIDINE DERIVATIVES FOR THE TREATMENT OR PREVENTION OF INFLUENZA OR CORONAVIRUS INFECTIONS | Emory University (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | VON BORSTEL REID W (US) | 2001-09-27 | — | — | US | disclosed |
| EP-0594667-B1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO NEURON INC (US) | 2001-09-19 | — | — | EP | disclosed |
| US-5968914-A | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | PRO-NEURON, INC. (US) | 1999-10-19 | — | — | US | disclosed |
| US-5736531-A | ADMINISTERING TO TREAT AND PREVENT TOXICITY | PRO-NEURON, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| WO-1994026761-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| US-4939156-A | Antitumor agents | MEIJI SEIKA KAISHA, LTD. (JP) | 1990-07-03 | — | — | US | disclosed |
| EP-0299413-A1 | New tetramethyl-cis-diaza-bicyclo[4.2.0]octane-3,5-dione derivatives having a differentiation-inducing activity | MEIJI SEIKA KAISHA LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
| US-4691012-A | INHIBITOR OF METASTASIS OF CANCER CELLS | MECT CORPORATION (JP) | 1987-09-01 | — | — | US | disclosed |
| US-4447600-A | IMMUNOSUPPRESSIVE AGENTS | KANTO ISHI PHARMACEUTICAL CO., LTD. (JP) | 1984-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628181-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | TYMP, ENTPD5, ADA | SLC28A1 61/4885SLC28A2 56/4885SLC29A1 57/4885 |
| US-20260055125-A1 | LIGAND-ASSISTED DEOXYGENATION OF PHOSPHATES TO FORM NITROGEN-CONTAINING PHOSPHORUS(V) PRECURSORS AND THEIR SUBSEQUENT CONVERSION TO VARIOUS OXYPHOSPHORUS COMPOUNDS | CA2, CA4, CA6 | SLC28A1 462/4885SLC28A2 406/4885SLC29A1 254/4885 |
| US-12551497-B2 | N4-hydroxycytidine and derivatives and anti-viral uses related thereto | NSUN2, MTAP, NSUN3 | SLC28A1 61/4885SLC28A2 115/4885SLC29A1 252/4885 |
| US-20230293566-A1 | N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto | TYMP, ADA, CDA | SLC28A1 68/4885SLC28A2 65/4885SLC29A1 59/4885 |
| US-20010025032-A1 | TREATMENT OF CHEMOTHERAPEUTIC AGENT AND ANTIVIRAL AGENT TOXICITY WITH ACYLATED PYRIMIDINE NUCLEOSIDES | TYMP, NUDT1, UNG | SLC28A1 100/4885SLC28A2 113/4885SLC29A1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.